About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cosmos Health Successfully Completes Second Phase of CCX0722 Development, an Innovative Product for Obesity and Weight Management: Significant Step in Bringing Product to the Multi-Billion-Dollar Market

By: ACCESSWIRE

CHICAGO, IL / ACCESSWIRE / June 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ: COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the successful completion of the second phase in the development of the CCX0722 product and its extensions, an innovative solution for obesity and weight management.

The Company believes that this represents a significant advancement in the fight against obesity and metabolic syndrome, offering a multifunctional mechanism of action. Our optimized product harnesses the power of a unique formulation that serves as an effective appetite suppressant and a catalyst for energy metabolism. By effectively absorbing and retaining substantial amounts of water, it aids in appetite control while stimulating the body's energy metabolism.

With the completion of these development phases, clinical trials for CCX0722 are scheduled to commence in the fourth quarter of 2023. This milestone represents a significant step forward in bringing this transformative product to market.

Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "Innovative research and development can have a game-changing impact for Cosmos, and our best-in-class team is up to the task of delivering groundbreaking solutions. We are one step closer to launching this transformative product, which we strongly believe can become a leader within the multi-billion-dollar obesity and weight management market. We remain steadfast in affirming our dedication to addressing the diverse needs and requirements of consumers battling obesity and metabolic syndrome. Our mission is to develop a comprehensive CCX product line that caters to the unique challenges faced by individuals seeking effective solutions for weight management. Cosmos is committed to empowering individuals to achieve healthier lives. Stay tuned for more updates on our groundbreaking CCX product line as we continue our journey towards a healthier future."

According to Grand View Research, the global weight management market was valued at USD 142.58 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 9.94% from 2023 to 2030. The worldwide increase in obesity is driving market growth for pharmaceutical and nutraceutical remedies due to the rising prevalence of related chronic diseases such as diabetes, hypertension, and orthopedic diseases.

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos Health has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmoshealthinc.com and www.skypremiumlife.com.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

SOURCE: Cosmos Health Inc.



View source version on accesswire.com:
https://www.accesswire.com/762680/Cosmos-Health-Successfully-Completes-Second-Phase-of-CCX0722-Development-an-Innovative-Product-for-Obesity-and-Weight-Management-Significant-Step-in-Bringing-Product-to-the-Multi-Billion-Dollar-Market

More News

View More
Biotech Breakouts: 3 Stocks With Massive Upside Potential
Via MarketBeat
Tickers IBRX MAZE VKTX
Powering Up: A Buy Rating Signals GE Vernova's AI Tailwinds
Via MarketBeat
Topics Artificial Intelligence Economy Energy
Tickers GEV
The Side of Rate Cuts Nobody Is Telling You About
Via MarketBeat
Topics Bonds Economy
Tickers CLSK IAU MP SPY TLT
Dave & Buster’s Stock: Is Now the Time to Make a PLAY?
Via MarketBeat
Tickers PLAY
Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing?
Via MarketBeat
Tickers LULU NKE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.